Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nextage TherapeuticsXTAE:NXTG 8 FCF Margin % is -210.38% as of Dec. 2025. GuruFocus rates XTAE:NXTG with a GF Score™ of 8/100 and a GF Value™ of ₪0.31 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 962 Drug Manufacturers companies, Nextage Therapeutics ranks worse than 93.76% on this metric.
The historical data trend for Nextage Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:NXTG vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nextage Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nextage Therapeutics FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nextage Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Nextage Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nextage Therapeutics (XTAE:NXTG) has a FCF Margin % of -210.38% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nextage Therapeutics and its competitors. According to the industry distribution chart, Nextage Therapeutics ranks #902 out of 962 companies in the Drug Manufacturers industry, placing it in the top 93.8%.
Is Nextage Therapeutics' FCF Margin % too high?
Nextage Therapeutics' current FCF Margin % is -210.38%. Based on the distribution chart, Nextage Therapeutics ranks #902 out of 962 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nextage Therapeutics has a GF Score™ of 8/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nextage Therapeutics' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nextage Therapeutics ranks #902 out of 962 companies for FCF Margin %. This places Nextage Therapeutics in the lower half of its industry. The industry median FCF Margin % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.48, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nextage Therapeutics and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nextage Therapeutics's current FCF Margin % is -210.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nextage Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nextage Therapeutics (XTAE:NXTG) is currently considered Modestly Overvalued. The stock's GF Value™ is ₪0.31, compared to a current price of ₪0.39 — trading 25.8% above its estimated fair value. The current FCF Margin % is -210.38%. Nextage Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Nextage Therapeutics (XTAE:NXTG), the current FCF Margin % is -210.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nextage Therapeutics (XTAE:NXTG) Overvalued in 2026?
Based on GuruFocus' analysis, Nextage Therapeutics stock appears to be overvalued.
The current stock price of ₪0.39 is trading 25.8% above its estimated GF Value™ of ₪0.31.
GuruFocus considers Nextage Therapeutics to be Modestly Overvalued.
Key valuation signals for XTAE:NXTG:
FCF Margin %: -210.38%
GF Value™: ₪0.31 vs. price of ₪0.39 (25.8% above fair value)
No single metric tells the full story. See the XTAE:NXTG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.
8GF Score
Get the complete analysis for XTAE:NXTG
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:NXTG has been successfully added to your 
